KRAS and familial pancreatic carcinoma: The KRAS oncogene is known to play a crucial role in the initiation and progression of pancreatic cancer, with G12D (c.35G>A)/V (c.35G>T)/R (c.34G>C) mutations accounting for more than 88.8% of mutation cases 6.